Table 1. Global population baseline characteristics.
| Non-adherent Group | Nephrocare Group | Global population | p | |
|---|---|---|---|---|
| Number | 3485 | 11174 | 14659 | |
| Age (years) (median, pc 25–75) | 71.0 (60.0–78.0) | 70.0 (61.0–77.0) | 70.0 (60.0–77.0) | 0.015a |
| Age groups: ≤ 40 years, n (%) | 230 (6.6%) | 705 (6.3%) | 935 (6.4%) | 0.540b |
| 41–64 years n (%) | 931 (26.7%) | 3083 (27.6%) | 4014 (27.4%) | 0.539 b |
| ≥65 years n (%) | 2324 (66.7%) | 7386 (66.1%) | 9710 (66.2%) | 0.628 b |
| Sex Male, n (%) | 2048 (58.8%) | 6296 (56.3%) | 8344 (56.9%) | 0.012 b |
| Health provider | 0.000 b | |||
| Public n (%) | 1317 (37.8%) | 3743 (33.5%) | 5060 (34.5%) | |
| Private-Non-for-profit n(%) | 2168 (62.2%) | 7431 (66.5%) | 9599 (65.5%) | |
| SBP initial (mmHg) (median, pc 25–75) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 0.020 b |
| DBP initial (mmHg) (median, pc 25–75) | 80 (70–80) | 80 (70–80) | 80 (70–80) | 0.850 b |
| Nefropathies | ||||
| Vascular, n (%) | 1731 (49.9%) | 5256 (47.2%) | 6987 (47.8%) | 0.000 b |
| Diabetics, n (%) | 517 (14.9%) | 1383 (12.4%) | 1900 (13.0%) | |
| Obstructive Tubulo-intersticial, n (%) | 216 (6.2%) | 581 (5.2%) | 797 (5.5%) | |
| Glomerulopathies, n (%) | 102 (2.9%) | 553 (5.0%) | 655 (4.5%) | |
| Cardiovascular risk factors and Comorbidities | ||||
| Arterial Hypertension, n (%) | 3027 (86.9%) | 9828 (88.0%) | 12855 (87.7%) | 0.086 b |
| Diabetes, n (%) | 1404 (40.3%) | 4049 (36.2%) | 5453 (37.2%) | 0.000 b |
| Smoking, n (%) | 251 (7.2%) | 739 (6.6%) | 990 (6.8%) | 0.230 b |
| Obesity, n (%) | 1098 (39.0%) | 3480 (39.1%) | 4578 (39.1%) | 0.913 b |
| Ischaemic heart disease, n (%) | 715 (20.5%) | 2152 (19.3%) | 2867 (19.6%) | 0.106 b |
| Stroke, n (%) | 174 (5.0%) | 542 (4.9%) | 716 (4.9%) | 0.722 b |
| Heart failure, n (%) | 317 (9.1%) | 830 (7.4%) | 1147 (7.8%) | 0.002 b |
| Lower limbs artery disease, n (%) | 188 (5.4%) | 537 (4.8%) | 725 (4.9%) | 0.165 b |
| eGFR initial (ml/min/1.73 m2) (median, pc 25–75) | 44.37 (33.51–57.52) | 39.94 (29.91–51.67) | 40.89 (30.74–53.13) | 0.000a |
| CKD stages at inclusion | ||||
| I, n (%) | 277 (7.9%) | 692 (6.2%) | 969 (6.6%) | 0.230 b |
| II, n (%) | 491 (14.1%) | 1053 (9.4%) | 1544 (10.5%) | |
| III, n (%) | 2121 (60.9%) | 6604 (59.1%) | 8725 (59.5%) | |
| IV, n (%) | 521 (14.9%) | 2498 (22.4%) | 3019 (20.6%) | |
| V, n (%) | 75 (2.2%) | 327 (2.9%) | 402 (2.7%) | |
| Proteinuria | ||||
| No proteinuria | 2438 (70.0%) | 7778 (69.6%) | 10216 (69.7%) | 0.253 b |
| <500 mg/day (or PCR< 500 mg/g), n (%) | 554 (15.9%) | 1700 (15.2%) | 2254 (15.4%) | |
| ≥500 mg/day (or PCR≥500 mg/g), n (%) | 493 (14.1%) | 1696 (15.2%) | 2189 (14.9%) | |
| Initial treatment | ||||
| RASB n (%) | 2028 (58.2.%) | 6958 (62.3%) | 8986 (61.3%) | 0.000 b |
CV = Cardiovascular comorbidities # = ischemic heart disease, chronic heart failure, peripheral arteriopathy and/or stroke.
SBP = Systolic blood pressure, DBP = Diastolic blood pressure, PCR = urine protein-creatinine ratio, RASB = Renin-angiotensin system blockade.
Statistics: aTest Mann Whitney,
b test Chi2.